<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id>
<journal-title-group>
<journal-title>Alzheimer's Research &amp; Therapy</journal-title>
</journal-title-group>
<issn pub-type="epub">1758-9193</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30902061</article-id>
<article-id pub-id-type="pmc">6429815</article-id>
<article-id pub-id-type="publisher-id">475</article-id>
<article-id pub-id-type="doi">10.1186/s13195-019-0475-2</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer’s disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hishimoto</surname>
<given-names>Akitoyo</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pletnikova</surname>
<given-names>Olga</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lang</surname>
<given-names>Doyle Lu</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Troncoso</surname>
<given-names>Juan C.</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Egan</surname>
<given-names>Josephine M.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8477-6452</contrib-id>
<name>
<surname>Liu</surname>
<given-names>Qing-Rong</given-names>
</name>
<address>
<phone>(410) 558-8592</phone>
<email>qliu@mail.nih.gov</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1092 3077</institution-id><institution-id institution-id-type="GRID">grid.31432.37</institution-id><institution>Department of Psychiatry, </institution><institution>Kobe University Graduate School of Medicine, </institution></institution-wrap>7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017 Japan </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution>Departments of Pathology, Neuropathology Division, </institution><institution>Johns Hopkins University School of Medicine, </institution></institution-wrap>600 North Wolfe Street, Baltimore, MD 21205 USA </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9372 4913</institution-id><institution-id institution-id-type="GRID">grid.419475.a</institution-id><institution>Lab of Clinical Investigation, </institution><institution>NIA-NIH, </institution></institution-wrap>251 Bayview Blvd, Baltimore, MD 21224 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>21</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>11</volume>
<elocation-id>28</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">Synaptic damage precedes neuron death in Alzheimer’s disease (AD). Neurexins, <italic>NRXN1</italic>, <italic>NRXN2,</italic> and <italic>NRXN3</italic>, are presynaptic adhesion molecules that specify neuron synapses and regulate neurotransmitter release. Neurexins and postsynaptic neuroligins interact with amyloid beta oligomer (AβO) deposits in damaged synapses. <italic>NRXN3</italic> gene variants have been associated with autism, addiction, and schizophrenia, however, not fully investigated in Alzheimer’s disease. In the present study, we investigated an AD association of a 3′-splicing allele of rs8019381 that produces altered expression of transmembrane or soluble <italic>NRXN3</italic> isoforms.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">We carried out RT-PCR (reverse transcription polymerase chain reaction), PCR-RFLP (PCR and restriction fragment length polymorphism), Sanger sequencing, and in situ hybridization (ISH) assays for <italic>NRXN3</italic> neuron expression and genotyping. Genetic associations were analyzed by <italic>χ</italic><sup>2</sup> tests, and ISH signals were analyzed by FISH v1.0 module of Indica Labs HALO software.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">We previously identified a functional haplotype in the 3′ region of neurexin 3 (<italic>NRXN3</italic>) gene that alters the expression ratios between <italic>NRXN3</italic> transmembrane and soluble isoforms. In this study, we found that expression and ratio of transmembrane and soluble <italic>NRXN3</italic> isoforms were reduced in AD postmortem brains and inversely correlated with inflammasome component <italic>NLRP3</italic> in AD brain regions. The splicing haplotype related to the transmembrane and soluble <italic>NRXN3</italic> expression was associated with AD samples with <italic>P</italic> = 6.3 × 10<sup>−5</sup> (<italic>odds ratio = 2.48</italic>) and interacted with <italic>APOE</italic> genotypes.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">We found that the SNP rs8019381 of <italic>NRXN3</italic> that is located adjacent to splicing site #5 (SS#5) interacts with the <italic>APOE</italic> ε4 haplotype and alters <italic>NRXN3</italic> transmembrane or soluble isoform expression in AD postmortem cortex. Dysregulation of presynaptic <italic>NRXN3</italic> expression and splicing might increase neuron inflammation in AD brain.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Alzheimer’s disease</kwd>
<kwd>Neurexins</kwd>
<kwd>Endocannabinoids</kwd>
<kwd>Apolipoprotein E</kwd>
<kwd>Alternative splicing</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>IRP/NIA/NIH</institution>
</funding-source>
<award-id>AG-000291-11</award-id>
<principal-award-recipient>
<name>
<surname>Egan</surname>
<given-names>Josephine M.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id>
<institution>National Institutes of Health</institution>
</institution-wrap>
</funding-source>
<award-id>P50AG05146</award-id>
<principal-award-recipient>
<name>
<surname>Troncoso</surname>
<given-names>Juan C.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par23">Non-familial and late-onset Alzheimer’s disease (AD) is a common cause of dementia in the elderly. Emphases on classical AD neuropathological features, Aβ neuritic plaques (Aβ-NPs), neurofibrillary tangles (NFTs), and neuropil threads are increasingly acknowledged to be accompanied by disrupted synaptic contacts and impaired glutamatergic neurotransmission [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. While the ε4 allele of apolipoprotein E (<italic>APOE</italic>) gene makes a large contribution to the genetic bases of interindividual differences in vulnerability to AD, the sizable genetic influences that remain after accounting for <italic>APOE</italic> are likely to arise from polygenic and/or rarer variants that each makes modest contributions to overall disease vulnerability.</p>
<p id="Par24">Diffuse Aβ fibrillar plaques are often observed in postmortem human brains with normal cognitive function [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. Pathological Aβ plaque formation around synapses with AβO deposit correlates with memory loss and synapse dysfunction [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Neurexins were discovered as α-latrotoxin (venom of black widow spider) receptors [<xref ref-type="bibr" rid="CR9">9</xref>] and function as presynaptic cell adhesion molecules [<xref ref-type="bibr" rid="CR10">10</xref>] that help to regulate the release of neurotransmitters, specify, and stabilize classical synapses, including the glutamatergic synapses that provide a focus for research in AD [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Neurexin genes are among the largest genes (greater than one million base pairs) in the human genome, and the three mammalian neurexin genes <italic>NRXN1</italic>, <italic>NRXN2,</italic> and <italic>NRXN3</italic> each display differential splicing events that provide thousands of neurexin isoforms on a background of longer α-neurexin and shorter β-neurexin that arise from the use of alternative promoters [<xref ref-type="bibr" rid="CR11">11</xref>]. The larger α-neurexins contain three EGF-like (epidermal growth factor) domains each of which flanked by two LNS (lamin-neurexin-sex hormone-binding globulin) domains, a single transmembrane domain, and intracellular PDZ (<italic>PSD95</italic>-<italic>Dlg1</italic>-<italic>Zo1</italic>) domain that interact with intrasynaptic proteins [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Specifically, α-neurexins are coupled to presynaptic calcium channels to regulate neurotransmitter release [<xref ref-type="bibr" rid="CR13">13</xref>] and interact with postsynaptic neuroligins, leucine-rich repeat transmembrane proteins (<italic>LRRTM</italic>s), calsyntenins (<italic>CLSTN</italic>), α-dystroglycan (<italic>DAG1</italic>), GABA<sub>A</sub>-receptors (<italic>GABRA</italic>s), latrophilins (<italic>ADGRL</italic>s), cerebellin (<italic>CBLN</italic>)-glutamate dehydrogenase (<italic>GLUD</italic>) complexes, synaptic cleft secreted neurexophilins (<italic>NXPH</italic>s), and intracellular PDZ-binding proteins [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Neurexins’ intracellular PDZ domains can bind to <italic>MINT1</italic>, <italic>MINT2</italic>, and <italic>CASK</italic> proteins [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>] that themselves bind to and stabilize the transmembrane form of amyloid precursor protein (<italic>APP</italic>) [<xref ref-type="bibr" rid="CR18">18</xref>]. <italic>MINT1</italic> and <italic>MINT2</italic> are adaptor proteins that complex with conserved motifs in <italic>APP</italic>’s C-terminal region to stabilize <italic>APP</italic> transmembrane forms and reduce secretion of pathogenic Aβ cleavage products [<xref ref-type="bibr" rid="CR19">19</xref>]. It is thus even possible that <italic>NRXN</italic>s-<italic>MINT</italic>s interaction complexes could alter <italic>APP</italic> protein processing. Soluble or secreted α-<italic>NRXN3</italic> is produced by including extra exon 23 with four different intra-exonal spliced sites that encode four premature stop codons that abolishes the transmembrane and intracellular PDZ domains [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The smaller β-neurexin contains one LNS domain (no EGF domain), a transmembrane domain, and an intracellular PDZ domain. The β-neurexin acts as a brake for endocannabinoid 2-AG (2-arachidonoylglycerol) synthesis that retrogradely regulates presynaptic cannabinoid receptor 1 (CB1R)-mediated depolarization-induced suppression of excitation on AMPA and NMDA receptors that are involved in excitatory postsynaptic currents (EPSCs) [<xref ref-type="bibr" rid="CR22">22</xref>]. <italic>APP</italic> cleavage enzymes of α- and γ-secretases can process β-<italic>NRXN3</italic> into an N-terminal extracellular domain (80 kDa) and a C-terminal intracellular domain (12 kDa). The enzymatic activities are altered by several single nucleotide polymorphisms (SNPs) of γ-secretase subunit presenilin 1 (<italic>PSEN1</italic>) that contribute to early-onset forms of familial AD [<xref ref-type="bibr" rid="CR23">23</xref>]. Recent data identify roles of neurexin isoforms in several complex neuropsychiatric phenotypes that include autism [<xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR26">26</xref>], addiction [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], and schizophrenia [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p>
<p id="Par25"><italic>NRXN3</italic> mRNA is the second most reduced gene after vacuolar H<sup>+</sup>-ATPase subunit gene <italic>ATP6V1E1</italic> in AD hippocampus identified by bioinformatic analysis of AD and aging Gene Expression Omnibus (GEO) databases [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. We have identified 3′ region of <italic>NRXN3</italic> haplotypes that are tagged by alleles of the SNP rs8019381, which is located near the end of <italic>NRXN3</italic>’s exon 23 at a key splicing site [<xref ref-type="bibr" rid="CR20">20</xref>]. Alleles of rs8019381 tagged <italic>NRXN3</italic> produce the splice variants that include or exclude exon 23 coding for a single transmembrane domain; thus, transmembrane or soluble <italic>NRXN3</italic> isoforms are transcribed and translated, respectively [<xref ref-type="bibr" rid="CR20">20</xref>]. <italic>NRXN3</italic> is expressed in neurons in brain regions that are implicated in mnemonic processes and in dementia-associated AD pathologies. For example, <italic>NRXN3</italic> is expressed in the cerebral cortex and in the hippocampus that contains AD-related senile plaques and neurofibrillary tangles [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Differences in the properties of synapses in these regions could alter brain connectivity, and the altered ratio of transmembrane and soluble <italic>NRXN3</italic> isoforms could lead to pathological AβΟ accumulation at synapses.</p>
<p id="Par26">We have thus characterized the patterns of expression of total <italic>NRXN3</italic>, α-<italic>NRXN3</italic> and β-<italic>NRXN3</italic>, and four <italic>NRXN3</italic> transmembrane and soluble splice variants in mRNAs extracted from postmortem middle frontal gyrus from pathologically confirmed AD and control individuals. We have sought AD-related differences in frequencies of <italic>NRXN3</italic> haplotypes and tested whether the <italic>NRXN3</italic> associations are dependent on the <italic>APOE</italic> genotype. Finally, we have found evidence for <italic>NRXN3</italic> association and interaction with <italic>APOE</italic> genotypes in previously reported genome-wide association datasets and for <italic>NRXN3</italic> inverse correlation with inflammasome component <italic>NLRP3</italic> in neurons of the AD hippocampus and cortex. Taken together, these data support contributions for common human <italic>NRXN3</italic> haplotypes and altered <italic>NRNX3</italic> transmembrane and soluble isoform expression in AD brain.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<sec id="Sec3">
<title>Subjects: human samples</title>
<p id="Par27">Middle frontal gyrus postmortem brain samples of 121 European-American AD (38 men and 83 women with mean age 80.3 ± 9.6) were obtained from the Division of Neuropathology, the Department of Pathology, the Johns Hopkins University School of Medicine (JHUSOMI), whose diagnoses were all confirmed by autopsy [<xref ref-type="bibr" rid="CR35">35</xref>].</p>
<p id="Par28">Additional European-American comparison groups comprising 349 subjects were examined to document the distribution of <italic>NRXN3</italic> polymorphism in the general American Caucasian population of the USA. One hundred sixty samples (107 men and 53 women with mean age 36.1 ± 16.2) were obtained from Maryland Brain Bank (UMD) whose geographical location is close to that of AD subject collection. One hundred eighty-nine unrelated subjects (42 men and 147 women with mean age 51.2 ± 14.9) were selected from pedigrees from the Collaborative Study on the Genetics of Alcoholism (COGA) [<xref ref-type="bibr" rid="CR36">36</xref>]. We explored mRNA levels of <italic>NRXN3</italic> isoforms in middle frontal gyrus postmortem samples from 58 pathologically confirmed AD subjects and 48 control subjects. We also explored the association between this <italic>NRXN3</italic> haplotype and AD with 121 pathologically confirmed AD subjects and 349 control subjects.</p>
</sec>
<sec id="Sec4">
<title>RNA isolation and cDNA synthesis</title>
<p id="Par29">Total RNA was extracted from the larger sized middle frontal gyrus samples available from 58 of the autopsy-confirmed European-American AD patients and 48 normal individuals dying without neurological disease (40 females/18 males, mean age ± SD; 81.2 ± 10.0, PMI; 11.4 ± 6.4 from JHMI and 11 females/37 males, mean age ± SD; 47.6 ± 19.7, PMI; 11.9 ± 6.0 from JHMI and UMD) using Trizol (Thermo Fisher, Waltham, MA) protocol. Single-strand cDNA was synthesized from total RNA using SuperScript™ III One-Step RT-PCR System (Invitrogen, Carlsbad, CA, USA). Electrophoresis of all RNAs used for quantitative PCR revealed sharp 18S and 28S ribosomal RNA bands; four samples with evidence for RNA degradation were eliminated on this basis.</p>
</sec>
<sec id="Sec5">
<title>Quantitative RT-PCR</title>
<p id="Par30">For quantitative real-time PCR assessments of <italic>NRXN3</italic> mRNAs, isoform-specific primers and minor groove-binding (MGB) TaqMan probes were designed using Primer Express Software (Table <xref ref-type="table" rid="Tab1">1</xref>), common <italic>NRXN3</italic> TaqMan probe (Hs01028186_m1), and endogenous control glyceraldehyde-3-phosphate dehydrogenase (<italic>GAPDH</italic>, Vic-labeled) which were ordered from Thermo Fisher (Cat#4326317E, Thermo Fisher Scientific, Waltham, MA, USA). The relative fold change is calculated using the formula 2^(−△△<italic>C</italic><sub><italic>t</italic></sub>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Real-time PCR primers and MGB Fam-TaqMan probes for <italic>NRXN3</italic> isoforms</p></caption><table frame="hsides" rules="groups"><thead><tr><th>
<italic>NRXN3</italic>
</th><th>Forward primers</th><th>Reverse primers</th><th>MGB probes</th></tr></thead><tbody><tr><td>Hs01028186_m1</td><td>NRXN3 TaqMan gene expression assay</td><td></td><td></td></tr><tr><td>ex 22a24a</td><td>TGATCTTGTTTCATCTGCTGAATG</td><td>AAGGTGCACGAGTAGCAATAG</td><td>CCGAGTACAGGAGGTG</td></tr><tr><td>ex 22a24b</td><td>TGATCTTGTTTCATCTGCTGAATG</td><td>TGCTTTGTAGCCACCTTCGA</td><td>CCGAGTACAGATAAGAGTC</td></tr><tr><td>ex 22a24c</td><td>TGATCTTGTTTCATCTGCTGAATG</td><td>CCCGGAACCCGTCTGATT</td><td>CCGAGTACAGCAAAC</td></tr><tr><td>ex 22a23a</td><td>AGATGATCTTGTTTCATCTGCTGAA</td><td>CGGAGTGATCTAGCTGCATTAGAG</td><td>CCGAGTACAGCCAGAAG</td></tr><tr><td>ex α1-2</td><td>GACATACAGACAGATCCCAAATCTTC</td><td>TCATGGTGCGGCCAGAA</td><td>AACTGGAAAGGTCTTTTC</td></tr><tr><td>ex β1-18</td><td>TTCCCCTGTTTCCCTTCGA</td><td>GCCCACCACTTTTCCCAAA</td><td>AGGACACGCTGGCG</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="Sec6">
<title>Genetic testing</title>
<p id="Par31">Genomic DNA was extracted from blood or tissue samples from the individuals noted in “human samples” above. DNA from most AD and control samples was extracted from the middle frontal gyrus brain tissues using Qiagen genomic DNA kits. Genomic DNA for other subjects was extracted from peripheral leukocytes as previously described [<xref ref-type="bibr" rid="CR37">37</xref>]. <italic>APOE</italic> polymorphisms were genotyped using PCR-RFLP assays as described [<xref ref-type="bibr" rid="CR38">38</xref>]. The rs8019381 SNP was genotyped by direct Sanger sequencing as described [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
</sec>
<sec id="Sec7">
<title>RNAscope in situ hybridization (ISH)</title>
<p id="Par32">Human postmortem hippocampus (1 control sample of Braak 0 and 3 AD samples of Braak 6) and middle temporal gyrus (2 control samples of each Braak 0, 1, and 2 and 2 AD samples of each Braak 4, 5, and 6) were used for triplex fluorescent ISH. Human RNAscope ISH probes were ordered from Advanced Cell Diagnostics Inc. (ACD, Hayward, CA, USA) for <italic>NRXN3</italic> in C2 channel (20 ZZ pairs targeted region 1095–2035 of NM_001105250.2; Cat No. 525431-C2), <italic>NLRP3</italic> in C1 channel (30 ZZ pairs targeted region 2627–4008 of NM_004895.4; Cat No. 478021), and <italic>NEUN</italic>/<italic>RBFOX3</italic> in C3 channel (20 ZZ pairs target region 720–2217 of NM_001082575.2; Cat No. 415591-C3). The positive control probes (Cat No. 320868) were <italic>POLR2A</italic> (C1 channel), <italic>PPIB</italic> (C2 channel), and <italic>UBC</italic> (C3 channel). The negative control probe was bacterium (<italic>Bacillus subtilis</italic>) gene <italic>DapB</italic> (Cat No. 320871). The cryostat sectioning of postmortem human brain samples, fixation, protease pretreatment, probe hybridization, pre-amplification, amplification, horseradish peroxidase reaction, and fluorescent labeling steps were described previously [<xref ref-type="bibr" rid="CR39">39</xref>]. Zeiss LSM 880 confocal microscope was used to image fluorescent labeling. Amplification × 20 images (two to three images for each brain sample) were analyzed by FISH v1.0 module included in HALO software with RNAscope ISH setting (Indica Labs, Corrales, NM, USA). The H-score [Σ<sub>bin0–4</sub> (ACD score or bin number × percentage of cells per bin)] were used to calculate mRNA expression for each probe based on the minimum intensity threshold (a value between 0 and 400). </p>
</sec>
<sec id="Sec8">
<title>Statistical analysis</title>
<p id="Par33">Genetic associations were analyzed by χ<sup>2</sup> tests. Deviations from Hardy-Weinberg equilibrium (HWE) were examined by <italic>χ</italic><sup>2</sup> test with <italic>P</italic> &lt; 0.05 as a deviation from HWE. Correction for multiple testing was not applied because of the a priori reason to focus on rs8019381 in this study. Power analyses used the program PS v2.1.31 [<xref ref-type="bibr" rid="CR40">40</xref>]. Comparison of the ages in AD between the rs8019381 SNP genotype groups was analyzed using ANOVA. Logistic regression analysis was also applied using phenotype as the dependent variable, and the age, gender, APOE ε4 allele, and rs8019381 genotypes as the independent variables. Statistical analyses of mRNA expression RT-PCR and ISH data were performed using PRISM (GraphPad Software, CA, USA) software. Differences in the mRNA expression levels based on phenotype (control vs AD or genotype CC vs CT and TT) were examined using two-tailed Mann-Whitney tests. Two-way ANOVA and two-tailed/unpaired Student’s <italic>t</italic> test using H-scores of ISH intensities were tested for any significant differences between <italic>NRXN3</italic> and <italic>NLRP3</italic> expressions in different Braak stages of MTG and HIP samples. Linear regression of H-scores of each ISH probe was used to fit straight lines through control and AD data sets with different Braak staining stages and statistically calculated for any significant differences. <italic>P</italic> &lt; 0.05 was considered significant for comparisons of expression levels. Spearman’s rank correlation coefficient analyses were used to assess the contributions of age, sex, and postmortem interval to the mRNA expression levels of each splice variant.</p>
</sec>
</sec>
<sec id="Sec9">
<title>Results</title>
<sec id="Sec10">
<title>α-<italic>NRXN3</italic> and β-<italic>NRXN3</italic> mRNA expression in AD middle frontal gyrus</title>
<p id="Par34">We compared expression of α-<italic>NRXN3</italic> and β-<italic>NRXN3</italic> in mRNAs extracted from the middle frontal cortices of human postmortem brain samples of AD and controls with different “splicing site 5 (SS#5)” <italic>NRXN3</italic> haplotypes defined by alleles of the rs8019381 SNP. Since controls displayed few rs8019381 T alleles, we compared control samples with CC genotypes to AD samples with CC genotype and to AD samples with either one or two T alleles (CT/TT). There were no significant differences between expression of α-<italic>NRXN3</italic> mRNA in CC controls vs AD patients with either CC or CT/TT genotypes (Fig. <xref ref-type="fig" rid="Fig1">1</xref>a; two-tailed Mann-Whitney <italic>P</italic> = 0.067 and <italic>P</italic> = 0.127, respectively). By contrast, when compared with control individuals with CC genotypes, β-<italic>NRXN3</italic> mRNA expression levels decreased by 30% and 48% in AD patients with CC and CT/TT genotypes, respectively (Fig. <xref ref-type="fig" rid="Fig1">1</xref>b; <italic>P</italic> = 0.0004 and <italic>P</italic> &lt; 0.0001, respectively). We identified a mild significant correlation between age and either α-<italic>NRXN3</italic> or β-<italic>NRXN3</italic> mRNA expression levels in the combined groups (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a; <italic>P =</italic> 0.0473, Spearman <italic>r</italic> = 0.193 and <italic>P =</italic> 0.0061, Spearman <italic>r</italic> = 0.2648, respectively). However, we identified neither a trend nor a significant correlation between age and either α-<italic>NRXN3</italic> or β-<italic>NRXN3</italic> mRNA expression levels in the control groups (Fig. <xref ref-type="fig" rid="Fig2">2</xref>b; <italic>P =</italic> 0.787, Spearman <italic>r</italic> = 0.040 and <italic>P =</italic> 0.386, Spearman <italic>r</italic> = 0.128, respectively). We also did not identify significant correlations between α-<italic>NRXN3</italic> and β-<italic>NRXN3</italic> mRNA expression levels in the AD group and age (Fig. <xref ref-type="fig" rid="Fig2">2</xref>c; <italic>P</italic> = 0.253, Spearman <italic>r</italic> = 0.153 and <italic>P</italic> = 0.186, Spearman <italic>r</italic> = 0.176, respectively). In these AD samples, the positive slope of this regression line does indicate trends toward less <italic>NRXN3</italic> expression in older individuals with AD phenotype. Neither gender nor postmortem intervals were correlated with these expression levels in control or AD groups (data not shown). In the AD subjects, there were no differences in expression of either α-<italic>NRXN3</italic> (<italic>P</italic> = 0.751) nor β-<italic>NRXN3</italic> isoforms (<italic>P</italic> = 0.863) in individuals with haplotypes marked by CC vs CT/TT genotypes.<fig id="Fig1"><label>Fig. 1</label><caption><p>α-<italic>NRXN3</italic> (<bold>a</bold>) and β-<italic>NRXN3</italic> (<bold>b</bold>) mRNA expressions in the middle frontal gyrus of control individuals (<italic>n</italic> = 44 individuals with rs8019381 CC genotype) and AD patients (<italic>n</italic> = 35 individuals with rs8019381 CC genotype and <italic>n</italic> = 23 individuals with CT or TT genotypes). Relative levels of each mRNA expression were obtained after normalization to <italic>GAPDH</italic>. Then, percentile change is obtained respective to an average of <italic>NRXN3-β</italic> mRNA in control individuals with CC genotype. **<italic>P</italic> &lt; 0.001, ***<italic>P</italic> &lt; 0.0001, calculated using two-tailed Mann-Whitney tests</p></caption><graphic id="MO1" xlink:href="13195_2019_475_Fig1_HTML"></graphic></fig><fig id="Fig2"><label>Fig. 2</label><caption><p><bold>a</bold> Correlation between age and either α-<italic>NRXN3</italic> or β-<italic>NRXN3</italic> mRNA expression levels in the control and AD combined groups (<italic>P =</italic> 0.0473, Spearman <italic>r</italic> = 0.193 and <italic>P =</italic> 0.0061, Spearman <italic>r</italic> = 0.2648, respectively). <bold>b</bold> Correlation between α-<italic>NRXN3</italic> and β-<italic>NRXN3</italic> mRNA expression levels in the control group and age (<italic>P</italic> = 0.787, Spearman <italic>r</italic> = 0.040 and <italic>p</italic> = 0.386, Spearman <italic>r</italic> = 0.128, respectively), and <bold>c</bold> in the AD group and age (<italic>P</italic> = 0.253, Spearman <italic>r</italic> = 0.153 and <italic>P</italic> = 0.186, Spearman <italic>r</italic> = 0.176, respectively). Δ<italic>C</italic><sub><italic>t</italic></sub> values of each isoform expression were obtained after normalization to <italic>C</italic><sub><italic>t</italic></sub> values of <italic>GAPDH</italic></p></caption><graphic id="MO2" xlink:href="13195_2019_475_Fig2_HTML"></graphic></fig></p>
</sec>
<sec id="Sec11">
<title>Genetic analysis</title>
<p id="Par35">Table <xref ref-type="table" rid="Tab2">2</xref> shows the genotype distribution and allele frequency of rs8019381 SNP for AD and control groups. The genotype distributions differed remarkably between the AD and control groups (<italic>χ</italic><sup>2</sup> = 15.587, df = 2, <italic>P</italic> = 0.000413). The minor allele frequency of the rs8019381 T allele was significantly greater for the AD group than for the control group (0.157:0.070, respectively; <italic>χ</italic><sup>2</sup> = 15.997, df = 1, <italic>P</italic> = 0.0000634). These results correspond to an odds ratio of 2.48 (95% confidence intervals 1.57–3.91) for AD in individuals with this T allele. Based on the observed allele frequency of the rs8019381 SNP, the current samples yielded the power of 0.894 for detecting nominally significant results. There was no significant effect of age on the distribution of rs8019381 genotypes in the AD group (<italic>P</italic> = 0.562 by one-way ANOVA). The rs8019381 genotype distributions also displayed no significant deviation from Hardy-Weinberg equilibrium in either the AD or control groups (data not shown).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Distribution of the <italic>NRXN3</italic> rs8019381 C/T SNP and <italic>APOE</italic> allele frequencies among the rs8019381 genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="2">Group</th><th colspan="3">Genotype<sup>a</sup></th><th colspan="2">Allele frequency</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>CC</th><th>CT</th><th>TT</th><th>C</th><th>T</th></tr></thead><tbody><tr><td colspan="8">rs8019381 genotype and allele frequencies<sup>b</sup></td></tr><tr><td colspan="2"> Control (<italic>n</italic> = 336)</td><td>291 (0.866)</td><td>43 (0.128)</td><td>2 (0.006)</td><td>0.930</td><td>0.070</td><td rowspan="2">Genotype: <italic>P</italic> = 0.00041 (<italic>X</italic><sup>2</sup> = 15.6, df = 2)<break></break>Allele: <italic>P</italic> = 0.000063 (<italic>X</italic><sup>2</sup> = 16.0, df = 1)</td></tr><tr><td colspan="2"> AD (<italic>n</italic> = 121)</td><td>86 (0.711)</td><td>32 (0.264)</td><td>3 (0.025)</td><td>0.843</td><td>0.157</td></tr><tr><td colspan="8">rs8019381 genotypes among <italic>APOE</italic> ε4 non-carriers and <italic>APOE</italic> ε4 carriers</td></tr><tr><td rowspan="2"> Control</td><td><italic>APOE</italic> ε4 non-carriers</td><td>216 (0.857)</td><td>35 (0.139)</td><td>1 (0.004)</td><td>0.927</td><td>0.073</td><td rowspan="4"><italic>APOE</italic> ε4 non-carriers VS.ε4 carriers in the AD<break></break>Genotype: <italic>P</italic> = 0.018 (<italic>X</italic><sup>2</sup> = 8.0, df = 2)<break></break>Allele: <italic>P</italic> = 0.000063 (<italic>X</italic><sup>2</sup> = 0.43, df = 1)</td></tr><tr><td><italic>APOE</italic> ε4 carriers</td><td>75 (0.893)</td><td>8 (0.095)</td><td>1 (0.012)</td><td>0.940</td><td>0.060</td></tr><tr><td rowspan="2"> AD</td><td><italic>APOE</italic> ε4 non-carriers</td><td>26 (0.722)</td><td>7 (0.195)</td><td>3 (0.083)</td><td>0.819</td><td>0.181</td></tr><tr><td><italic>APOE</italic> ε4 carriers</td><td>60 (0.706)</td><td>25 (0.294)</td><td>0 (0.000)</td><td>0.853</td><td>0.147</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Number of subjects (frequency)</p><p><sup>b</sup>rs8019381: Significant differences were found between the AD and the controls in either the genotype distribution (<italic>χ</italic><sup>2</sup> = 15.587, df = 2, <italic>P</italic> = 0.000413) or the allele frequencies (<italic>χ</italic><sup>2</sup> = 15.997, df = 1, <italic>P</italic> = 0.0000634)</p></table-wrap-foot></table-wrap></p>
<p id="Par36">We next investigated the <italic>APOE</italic> genotypes in these samples and sought possible interactions with the effects of the <italic>NRXN3</italic> haplotypes marked by the rs8019381 SNP (Table <xref ref-type="table" rid="Tab2">2</xref>). As expected, the <italic>APOE</italic> genotype and allele frequency distributions of the AD samples differed significantly from those of the control group (<italic>χ</italic><sup>2</sup> = 87.146, df = 5, <italic>P</italic> = 2.671 × 10<sup>−17</sup> and <italic>χ</italic><sup>2</sup> = 92.374, df = 2, <italic>P</italic> = 8.735 × 10<sup>−21</sup>, respectively; Table <xref ref-type="table" rid="Tab2">2</xref>).</p>
<p id="Par37">When we sought interactions between the rs8019381 SNP and <italic>APOE</italic> genotypes in the AD group, the rs8019381 genotype distributions displayed significant differences between <italic>APOE</italic> ε4 non-carriers and <italic>APOE</italic> ε4 carriers (<italic>χ</italic><sup>2</sup> = 8.043, df = 2, <italic>P</italic> = 0.0179). Among AD individuals, rs8019381 TT homozygotes were found only in those who did not carry <italic>APOE</italic> ε4 alleles. This difference provided significance for recessive analysis (comparing CC + CT vs TT) of the differences between AD <italic>APOE</italic> ε4 non-carriers and AD <italic>APOE</italic> ε4 carriers (<italic>χ</italic><sup>2</sup> = 6.317, df = 1, <italic>P</italic> = 0.012), though not for analyses of allele frequencies (<italic>χ</italic><sup>2</sup> = 0.429, df = 1, <italic>P</italic> = 0.513). These results contrasted with those in control samples, where we found that neither genotype distributions nor allele frequencies were significantly different between <italic>APOE</italic> ε4 non-carriers and <italic>APOE</italic> ε4 carriers (<italic>P</italic> = 0.428 and 0.541 for genotype and allele comparisons, respectively).</p>
<p id="Par38">Overall, significant associations between the rs8019381 genotypes and AD thus remained in both <italic>APOE</italic> ε4 non-carriers (<italic>P</italic> = 0.000403) and in <italic>APOE</italic> ε4 carriers (<italic>P</italic> = 0.00331). The allele frequencies for the rs8019381 SNP also differed significantly in AD vs control comparisons in both the <italic>APOE</italic> ε4 non-carriers (<italic>P</italic> = 0.00252) and <italic>APOE</italic> ε4 carriers (<italic>P</italic> = 0.00827). We also confirmed a significant effect of rs8019381 polymorphism on the AD phenotype considering for age, gender, and APOE ε4 allele (<italic>P</italic> = 0.00157, Table <xref ref-type="table" rid="Tab3">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Logistic regression analysis of rs8019381 C/T SNP on the AD phenotype considering for age, gender, and <italic>APOE</italic> ε4 allele</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5">Coefficients of bias-reduced logistic regression</th></tr><tr><th>Variable</th><th>Parameter</th><th>Standard error</th><th>Wald <italic>χ</italic><sup>2</sup></th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Intercept</td><td>− 13.917</td><td>1.528</td><td>− 9.107</td><td>&lt; 0.0001</td></tr><tr><td>Age</td><td>0.179</td><td>0.020</td><td>8.750</td><td>&lt; 0.0001</td></tr><tr><td>Gender</td><td>− 0.051</td><td>0.416</td><td>− 0.123</td><td>0.902</td></tr><tr><td><italic>APOE</italic> ε4 allele<sup>a</sup></td><td>1.691</td><td>0.403268658</td><td>4.194</td><td>0.000033</td></tr><tr><td>rs8019381 genotype<sup>b</sup></td><td>3.078</td><td>0.968</td><td>3.181</td><td>0.00157</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>For <italic>APOE</italic> ε4 allele analyses, ε4 non-carriers were coded as 0 and <italic>APOE</italic> ε4 carriers were coded as 1</p><p><sup>b</sup>For rs8019381 genotype analyses, each SNP was coded as 0 for major allele homozygotes, 0.5 for heterozygotes, and 1 for minor allele homozygotes</p></table-wrap-foot></table-wrap></p>
<p id="Par39">As anticipated for loci on distinct chromosomes, <italic>APOE</italic> (19q13) and <italic>NRXN3</italic> (14q24) markers displayed evidence for independent segregation in these samples. Neither the genotype distribution nor allele frequency of rs8019381 SNP was associated with the <italic>APOE</italic> allele frequency among the AD or control groups (<italic>P</italic><sub>AD</sub> = 0.061, <italic>P</italic><sub>CTL</sub> = 0.850 and <italic>P</italic><sub>AD</sub> = 0.600, <italic>P</italic><sub>CTL</sub> = 0.283 for genotypic and allelic comparisons, respectively).</p>
</sec>
<sec id="Sec12">
<title>Genetic variation and <italic>NRXN3</italic> SS#5 splice variants in AD</title>
<p id="Par40">Since the <italic>NRXN3</italic> haplotype tagged by rs8019381 (Fig. <xref ref-type="fig" rid="Fig3">3</xref>a) has been associated with altered patterns of expression of <italic>NRXN3</italic> splice variants that encode transmembrane vs soluble isoforms, we evaluated the distributions of these isoforms in control brains, which were virtually all from individuals with CC haplotypes, and in frontal cortex samples of AD brains from CC, CT, and TT individuals. We have previously noted that the predominant <italic>NRXN3</italic> transmembrane isoforms that arise from alternative splicing at SS#5 are exon 22a-24b, exon 22a-24c, and exon 22a-24a, while the predominant soluble isoform comes from exon 22a-23a-24a. We thus assessed the levels of these four isoforms (Fig. <xref ref-type="fig" rid="Fig3">3</xref>b).<fig id="Fig3"><label>Fig. 3</label><caption><p><bold>a</bold> The approximate location of rs8019381 and splicing patterns at the SS#5 of the <italic>NRXN3</italic> gene. The number of potential variants for the splicing site is 30. Exon 24 is the last exon of the gene that codes for the transmembrane region, cytoplasmic domain, and contains 3′UTR. Because any exon 23 isoforms include in-frame stop codons (depicted as asterisks), if it is inserted, soluble α-<italic>NRXN3</italic> and β-<italic>NRXN3</italic> can be produced from this gene. <bold>b</bold> The three major transmembrane isoforms and one major soluble isoform are investigated in the prefrontal cortex in individuals with AD (<italic>n</italic> = 58) and controls (<italic>n</italic> = 48). Each probe for the RT-PCR was designed across both exons. <bold>c</bold> Expression levels of total <italic>NRXN3</italic> mRNA in the middle frontal gyrus (MTG), middle temporal gyrus (MTG), and hippocampus (HIP)</p></caption><graphic id="MO3" xlink:href="13195_2019_475_Fig3_HTML"></graphic></fig></p>
<p id="Par41">The most prominent result of these assays, as with studies of total <italic>NRXN3</italic>, α-<italic>NRXN3</italic>, and β-<italic>NRXN3</italic> mRNA levels, was the reduced expression that was found for most of the isoforms in the AD postmortem middle frontal gyrus (MFG), middle temporal gyrus (MTG), and hippocampus (HIP) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>c). In comparison with one-half reduction of total <italic>NRXN3</italic> expression in the AD cortex, the exon 22a-24b variant that encodes the major transmembrane isoform was expressed at levels that were decreased, by 85% in AD subjects with either CC or CC/TT genotypes (<italic>P</italic> &lt; 0.0001 by two-tailed Mann-Whitney tests for both comparisons) (Fig. <xref ref-type="fig" rid="Fig4">4</xref>b). Levels of the exon 22a-24c variant, the second major transmembrane isoform were also decreased by 56% and 66% in AD patients with CC and with CC/TT genotypes when compared with control CC individuals (Fig. <xref ref-type="fig" rid="Fig4">4</xref>c; <italic>P</italic> &lt; 0.0001 by two-tailed Mann-Whitney test for both comparisons). Overall differences in mRNA expression levels for these two transmembrane isoforms between CC and CT/TT genotypes were not detected among the AD patients (<italic>P</italic> = 0.611 and 0.476 by two-tailed Mann-Whitney tests, respectively).<fig id="Fig4"><label>Fig. 4</label><caption><p><bold>a</bold>–<bold>c</bold> Expression levels of mRNAs encoding <italic>NRXN3</italic> transmembrane isoforms (exon 22a-24a, exon 22a-24b, and exon 22a-24c variants, respectively) and <bold>d</bold>
<italic>NRXN3</italic> soluble isoform (exon 22a-23a variant) in the middle frontal gyrus of control individuals (<italic>n</italic> = 44 individuals with rs8019381 CC genotype) and AD patients (<italic>n</italic> = 35 individuals with rs8019381 CC genotype and <italic>n</italic> = 23 individuals with CT or TT genotypes). Relative levels of each mRNA expression were obtained after normalization to GAPDH. Then, percentile change is obtained respective to an average of β-<italic>NRXN3</italic> mRNA in control individuals with CC genotype. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.001, ***<italic>P</italic> &lt; 0.0001, calculated using two-tailed Mann-Whitney tests</p></caption><graphic id="MO4" xlink:href="13195_2019_475_Fig4_HTML"></graphic></fig></p>
<p id="Par42">The major soluble <italic>NRXN3</italic> isoform, encoded by the exon 22a-23a variant mRNA was also decreased by 63% and 71% in AD patients with CC and CC/TT genotypes when compared with those in control individuals with CC genotypes (Fig. <xref ref-type="fig" rid="Fig4">4</xref>d; <italic>P</italic> &lt; 0.0001 by two-tailed Mann-Whitney test for both comparisons). Differences in mRNA expression levels between CC and CT/TT genotypes were not detected among the AD brains (<italic>P</italic> = 0.455 by two-tailed Mann-Whitney test).</p>
<p id="Par43">Closer examination revealed evidence for interactions between the clinical phenotype, the AD susceptible rs8019381 T allele, and expression of the exon 22a-24a mRNA that encodes a major transmembrane isoform (Fig. <xref ref-type="fig" rid="Fig4">4</xref>a). Expression of exon 22a-24a mRNA was decreased by 46% in AD patients with CT/TT genotypes when compared with those in control individuals with CC genotypes (<italic>P</italic> = 0.0002, two-tailed Mann-Whitney tests). Within the AD group, exon 22a-24a mRNA expression levels were also decreased by 46% in AD patients with CT/TT genotypes when compared with those with CC genotypes (<italic>P</italic> = 0.043 by two-tailed Mann-Whitney tests). By contrast, exon 22a-24a mRNA expression levels did not differ significantly between control and AD samples with CC genotypes (<italic>P</italic> = 0.180 by two-tailed Mann-Whitney test). These differences correlated with differences in the ratios between transmembrane and soluble isoform expression in CC vs CT/TT AD individuals, and the ratio differences reached the margin of statistical significance (Fig. <xref ref-type="fig" rid="Fig5">5</xref>). In AD patients, the ratios of transmembrane vs soluble isoforms were 25% greater in CT/TT than in CC subjects (<italic>P</italic> = 0.053 by two-tailed Mann-Whitney test and <italic>P</italic> = 0.044 by unpaired <italic>t</italic> test) despite that the overall ratio of the transmembrane and soluble isoforms decreased in AD brains. Interestingly, these ratios did not differ between AD patients with CT/TT genotypes vs those in control CC individuals (<italic>P</italic> = 0.331 by two-tailed Mann-Whitney tests).<fig id="Fig5"><label>Fig. 5</label><caption><p>Ratios of expression levels in total transmembrane isoforms to soluble isoform. In AD groups, ratios of transmembrane to soluble isoform show a significant difference between individuals with CC genotype and those with CT or TT genotypes. The ratios were increased by 25% in AD patients with CT or TT genotypes compared with AD with CC genotype (*<italic>P</italic> = 0.053 by two-tailed Mann-Whitney test and <italic>P</italic> = 0.044 by unpaired <italic>t</italic> test</p></caption><graphic id="MO5" xlink:href="13195_2019_475_Fig5_HTML"></graphic></fig></p>
</sec>
<sec id="Sec13">
<title>Inverse correlation of <italic>NRXN3</italic> with inflammasome component <italic>NLRP3</italic> in AD brains</title>
<p id="Par44">We carried out an ultra-sensitive RNAscope ISH assay to study the altered <italic>NRXN3</italic> expression at cellular levels in control and AD postmortem brain samples that were co-hybridized and co-stained with inflammasome component <italic>NLRP3</italic> [<xref ref-type="bibr" rid="CR41">41</xref>] and neuron marker <italic>NEUN</italic>/<italic>RBFOX3</italic>. All <italic>NRXN3</italic> and the majority of <italic>NLRP3</italic> signals were co-localized with <italic>NEUN</italic>/<italic>RBFOX3-</italic>positive neurons (Fig. <xref ref-type="fig" rid="Fig6">6</xref>). We found that the reduced <italic>NRXN3</italic> mRNA was inversely correlated with the increased <italic>NLRP3</italic> mRNA in <italic>NEUN</italic>/<italic>RBFOX3</italic>-positive neurons of the AD middle temporal gyrus (Fig. <xref ref-type="fig" rid="Fig6">6</xref>a–f) and hippocampus (Fig. <xref ref-type="fig" rid="Fig6">6</xref>g, h) samples. Two-tailed and unpaired Student’s <italic>t</italic> test using H-scores that represent <italic>NRXN3</italic> neuron expression was significantly higher than that of <italic>NLRP3</italic> at Braak 2 stage of MTG and significantly lower at Braak 6 stage in MTG and HIP (Fig. <xref ref-type="fig" rid="Fig7">7</xref>a). Two-way ANOVA analysis found significant differences of H-scores in HIP (<italic>F</italic><sub>1,14</sub> = 6.07; <italic>P</italic> = 0.0273) but not in MTG (<italic>F</italic><sub>1,28</sub> = 0.45; <italic>P</italic> = 0.4515) with different Braak stages; however, the interaction of <italic>NRXN3</italic> and <italic>NLRP3</italic> neuron expression in MTG and HIP at different Braak stages were very significant (<italic>P</italic> &lt; 0.0001). Linear regression analysis using H-score for each Braak number (0, 1, 2, 4, 5, 6) found that the differences of slopes of <italic>NRXN3</italic> and <italic>NLRP3</italic> were significant (<italic>F</italic><sub>1,8</sub> = 11.49; <italic>P</italic> = 0.0095) in MTG samples. <italic>NLRP3</italic> regression slope was significantly non-zero (<italic>F</italic><sub>1,4</sub> = 18.32; <italic>P</italic> = 0.0128), and <italic>NRXN3</italic> regression slope was not significantly non-zero (<italic>F</italic><sub>1,4</sub> = 0.98; <italic>P</italic> = 0.3773). The correlation was also simulated in control (Braak = 0) and AD (Braak = 6) in HIP samples. The linear regression lines for <italic>NRXN3</italic> and <italic>NLRP3</italic> intersected at 2.6 and 2.1 Braak grades in MTG and HIP samples, respectively (Fig. <xref ref-type="fig" rid="Fig7">7</xref>b). We did not observe any significant correlation of <italic>NEUN</italic>/<italic>RBFOX3</italic> with Braak stages (data not shown).<fig id="Fig6"><label>Fig. 6</label><caption><p><bold>a</bold>–<bold>h</bold> RNAscope in situ hybridization of control and AD brain samples with different Braak numbers Green represents <italic>NLRP3</italic>, yellow <italic>NRXN3</italic>, and magenta <italic>NEUN</italic>. The red arrow indicates colocalization of three probes in the same cell. H-score correlations of <italic>NRXN3</italic> and <italic>NLRP3</italic> intensities with Braak numbers. (<bold>a</bold>) MTG-Braak 0; (<bold>b</bold>) MTG-Braak 1; (<bold>c</bold>) MTG-Braak 2; (<bold>d</bold>) MTG-Braak 4; (<bold>e</bold>) MTG-Braak 5; (<bold>f</bold>) MTG-Braak 6; (<bold>g</bold>) HIP-Braak 0; (<bold>h</bold>) HIP-Braak 6</p></caption><graphic id="MO6" xlink:href="13195_2019_475_Fig6_HTML"></graphic></fig><fig id="Fig7"><label>Fig. 7</label><caption><p><bold>a</bold> Neuron expression of <italic>NRXN3</italic> and <italic>NLRP3</italic> in MTG and HIP of different Braak stages. <bold>b</bold> Linear regression of H-scores (<italic>Y</italic>-axis) of <italic>NRXN3</italic> and <italic>NLRP3</italic> with Braak numbers (<italic>X</italic>-axis) for MTG and HIP</p></caption><graphic id="MO7" xlink:href="13195_2019_475_Fig7_HTML"></graphic></fig></p>
</sec>
</sec>
<sec id="Sec14">
<title>Discussion</title>
<p id="Par45">We found that <italic>NRXN3</italic> gene haplotype interacts with the <italic>APOE</italic> ε4 haplotype, and the expression and ratio of its transmembrane and soluble isoforms were reduced in AD postmortem MFG. <italic>NRXN3</italic> mRNA level was inversely correlated with that of inflammasome component <italic>NLRP3</italic> in MTG AD neurons. The linear regression of <italic>NRXN3</italic> and <italic>NLRP3</italic> signals that intersected at Braak 2.1 for HIP and Braak 2.6 for MTG might indicate differential progression of Aβ fibrils in different brain regions. Previous studies by array tomography and electron microscopy find that AβO forms halo at synapses that attracts Aβ fibrils around damaged neurites [<xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR44">44</xref>]. The most prominent AD-associated susceptible genes and their altered expression/splicing/translation/PTM (posttranslational modifications), such as <italic>APP</italic> and <italic>PSEN1</italic> [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], <italic>APOE</italic> and <italic>APOER2</italic> [<xref ref-type="bibr" rid="CR46">46</xref>], <italic>PTK2B</italic> [<xref ref-type="bibr" rid="CR47">47</xref>], <italic>PPP3CA</italic> and <italic>PPP3R1</italic> [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>], and <italic>PIN1</italic> [<xref ref-type="bibr" rid="CR50">50</xref>], are involved in synaptic homeostasis. Dysregulation of presynaptic <italic>NRXN3</italic> might be an early event that triggers synaptic calcium dyshomeostasis and let AβO invasion at synapses. Subsequent dystrophic neurites and dysfunctional synapses stimulate <italic>NLRP3</italic>/caspase-1 and calcineurin/caspase-3 pathways that activate interleukin-1β and interleukin-18 [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>] and cause mitochondria impairment and apoptosis [<xref ref-type="bibr" rid="CR53">53</xref>], respectively. Aβ fibrils are at their peak when AD symptom just appears [<xref ref-type="bibr" rid="CR54">54</xref>], and <italic>NRXN3</italic> and <italic>NLRP3</italic> expression trajectories might serve as early diagnosis and therapeutic targets at early Braak 2–3 stages.</p>
<p id="Par46"><italic>NRXN3</italic> SNP rs8019381 was found to contribute to AD susceptibility. There is no information available for rs8019381 in previously reported genome-wide association studies for AD [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>] because of the relatively small haplotype block (14 kb) in the study. While no genomic markers that display strong linkage disequilibrium with rs8019381 are identified in the Translational Genomic Research Institute (TGen) datasets [<xref ref-type="bibr" rid="CR56">56</xref>], we identified rs2067730 that lies about 6 kb 5′ to rs8019381 in genome-wide association studies of clinically diagnosed AD vs control subjects of European ancestries who were recruited from Canadian memory clinics [<xref ref-type="bibr" rid="CR55">55</xref>]. Interestingly, like <italic>NRXN3</italic> rs801938, rs2067730 displays association with AD in this sample and appears to interact with the <italic>APOE</italic> genotype (<italic>P</italic> = 0.027).</p>
<p id="Par47">The magnitude of rs8019381 association suggests an odds ratio of 2.48, with a broad 95% confidence interval that encompasses 1.6–3.9. While this effect is much less than the large, oligogenic influence of <italic>APOE</italic> haplotypes on AD vulnerability, it is larger than many of the effects of other proposed polygenic variants listed in systematic meta-analysis presented on the AlzGene database [<xref ref-type="bibr" rid="CR57">57</xref>] or in two genome-wide association datasets that compare AD vs control samples [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. The effects of the <italic>NRXN3</italic> haplotype may be even larger in individuals with specific <italic>APOE</italic> haplotypes. Both the current dataset and data reported by Li et al [<xref ref-type="bibr" rid="CR55">55</xref>] provide evidence for significant interactions among <italic>APOE</italic> haplotypes and 3′ <italic>NRXN3</italic> haplotypes in AD.</p>
<p id="Par48">The reduced expression of total <italic>NRXN3</italic>, α-<italic>NRXN3</italic>, and β-<italic>NRXN3</italic> in samples of the cerebral cortex and hippocampus from pathologically confirmed AD and control brains formed the initial basis for implicating <italic>NRXN3</italic> in AD. These findings were accompanied by a significant reduction of ratios between transmembrane and soluble isoforms in AD individuals with rs8019381 CT or TT genotypes. These observations support the hypothesis that reduction of <italic>NRXN3</italic> transmembrane isoform alters synapse homeostasis, reduces neurotransmitter release, and promotes Aβ oligomerization and <italic>APOE</italic> dysfunction in synaptic degeneration [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Alternatively, the altered ratio might differentially interact with alternatively spliced isoforms of <italic>APP,</italic> causing increased Aβ production [<xref ref-type="bibr" rid="CR59">59</xref>].</p>
<p id="Par49">The associated <italic>NRXN3</italic> SNP rs8019381 is located at the junction of exon 23’s splicing donor site (23 base pairs downstream from the 3′ of exon 23), within a region that might alter splicing efficiency. The <italic>NRXN3</italic> haplotype studied here is likely to be different from other ethnic samples. The rs8019381 “T” allele frequency (0.07) of the control samples reported here (based on genotypes from 672 chromosomes) is similar to values obtained in unselected Europeans and European-Americans available (0.094 based on genotypes from 224 chromosomes) from dbSNP. African Yoruban rs8019381 frequency (0.198) is (based on genotypes of 180 chromosomes) higher than European population, and East Asian rs8019381 frequency is much lower than European and African populations, with none of the “T” allele detected in Chinese (based on genotypes of 90 chromosomes) and 0.006 detected in Japanese (based on genotypes of 172 chromosomes) HapMap samples. Additional studies will be necessary to identify more informative <italic>NRXN3</italic> rs8019381 for use in individuals with non-European heritage. Much of the evidence presented here provides an increased focus on the role of synaptic pathology in AD. Synapse losses can be documented with the first clear-cut evidence for dementia that are accompanied by synaptic toxicities conferred by <italic>APP</italic> [<xref ref-type="bibr" rid="CR60">60</xref>] and <italic>APOE</italic> mutations [<xref ref-type="bibr" rid="CR61">61</xref>]. The evidence in the current report suggests that Aβ and <italic>APOE</italic> synaptic pathologies are likely to interact with allele-specific alterations in gene expression of <italic>NRXN3</italic> transmembrane and soluble isoforms.</p>
<p id="Par50">An astronomical number of synapses derived from about 86 billion human brain neurons [<xref ref-type="bibr" rid="CR62">62</xref>] are dynamic throughout the human life span, and their damage precedes neuron death due to Aβ oligomer (AβΟ) toxicity in AD [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Substantial microscopic Aβ plaques are observed in old adult brains with intact cognition function [<xref ref-type="bibr" rid="CR6">6</xref>]; however, nano-synaptic-space distribution of AβO is less known and neurexin complexes are known partners of Aβ [<xref ref-type="bibr" rid="CR8">8</xref>]. Complex neurexin alternative splicing codes define synaptic specificity, strength, plasticity [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], and vulnerability toward AβO [<xref ref-type="bibr" rid="CR64">64</xref>]. The trans-synaptic anterograde and retrograde signaling of the neurexin-neuroligin-endocannabinoid system [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>] provides an attractive pathway for AD therapeutic development. Modulation of presynaptic and postsynaptic endocannabinoid tone through CB1R [<xref ref-type="bibr" rid="CR67">67</xref>] and CB2R [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>], respectively, by their specific ligands might reduce neuron inflammasome and shift neurexin-neuroligin alternative splicing repertoire toward heathy synapses and reverse cognitive decline during aging [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. Neurexin peptides are significantly elevated in cerebrospinal fluid (CSF) of individuals with mild cognitive impairment (MCI), especially in patients with MCI progressing to AD dementia [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Conceptually, targeted tryptic peptide panels of specific neurexin isoforms will improve CSF early diagnosis for pre-symptomatic AD. Screening of effective neurexin and cannabinoid receptor ligands [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR74">74</xref>] and behavioral modulation of mental activities and nutrition intakes [<xref ref-type="bibr" rid="CR75">75</xref>] might help to improve synaptic health and prevent cognitive decline 10 years or more before AD symptom appearance.</p>
</sec>
<sec id="Sec15">
<title>Conclusion</title>
<p id="Par51"><italic>NRXN3</italic> rs8019381 SNP located at SS#5 splicing site was found to contribute to AD susceptibility and interact with the <italic>APOE</italic> ε4 haplotype. The altered expressions of <italic>NRXN3</italic> transmembrane and soluble isoforms were further reduced in susceptible rs8019381 heterozygous and homozygous alleles (CT or TT) in the AD postmortem cortex. The reduced <italic>NRXN3</italic> expression was inversely correlated with the increase of inflammasome component <italic>NLRP3</italic> expression in <italic>NEUN</italic>/<italic>RBFOX3</italic>-positive neurons in the AD brain.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AD</term>
<def>
<p id="Par5">Alzheimer’s disease</p>
</def>
</def-item>
<def-item>
<term>Aβ</term>
<def>
<p id="Par6">Amyloid beta</p>
</def>
</def-item>
<def-item>
<term>AβO</term>
<def>
<p id="Par7">Amyloid beta oligomer</p>
</def>
</def-item>
<def-item>
<term>CSF</term>
<def>
<p id="Par8">Cerebral spinal fluid</p>
</def>
</def-item>
<def-item>
<term>HIP</term>
<def>
<p id="Par9">Hippocampus</p>
</def>
</def-item>
<def-item>
<term>HWE</term>
<def>
<p id="Par10">Hardy-Weinberg equilibrium</p>
</def>
</def-item>
<def-item>
<term>LNS</term>
<def>
<p id="Par11">Lamin-neurexin-sex hormone-binding globulin domains</p>
</def>
</def-item>
<def-item>
<term>MCI</term>
<def>
<p id="Par12">Mild cognitive impairment</p>
</def>
</def-item>
<def-item>
<term>MFG</term>
<def>
<p id="Par13">Middle frontal gyrus</p>
</def>
</def-item>
<def-item>
<term>MTG</term>
<def>
<p id="Par14">Middle temporal gyrus</p>
</def>
</def-item>
<def-item>
<term>NFT</term>
<def>
<p id="Par15">Neurofibrillary tangles</p>
</def>
</def-item>
<def-item>
<term>PCR-RFLP</term>
<def>
<p id="Par16">PCR and restriction fragment length polymorphism</p>
</def>
</def-item>
<def-item>
<term>PDZ</term>
<def>
<p id="Par17"><italic>PSD95</italic>-<italic>Dlg1</italic>-<italic>Zo1</italic> domain</p>
</def>
</def-item>
<def-item>
<term>PMI</term>
<def>
<p id="Par18">Postmortem interval</p>
</def>
</def-item>
<def-item>
<term>PTM</term>
<def>
<p id="Par19">Posttranslational modification</p>
</def>
</def-item>
<def-item>
<term>RT-PCR</term>
<def>
<p id="Par20">Reverse transcription polymerase chain reaction</p>
</def>
</def-item>
<def-item>
<term>SNP</term>
<def>
<p id="Par21">Single nucleotide polymorphism</p>
</def>
</def-item>
<def-item>
<term>SS#5</term>
<def>
<p id="Par22">Splicing site 5</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>The authors acknowledge human DNA samples provided by Maryland Brain Bank (UMD) and the Collaborative Study on the Genetics of Alcoholism (COGA).</p>
<sec id="FPar1">
<title>Funding</title>
<p id="Par52">Intramural Research Programs (AG-000291-11) of NIA/NIH and the Johns Hopkins University Alzheimer’s Disease Research Center (NIH P50AG05146).</p>
</sec>
<sec id="FPar2" sec-type="data-availability">
<title>Availability of data and materials</title>
<p id="Par53">Data available on request from the author.</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>QRL, AH, and JME were responsible for the conception and design of the study. AH and QRL carried out the experiments and were responsible for the analysis, interpretation of the data, and drafting of the manuscript. DLL performed in the cryostat sectioning of the postmortem brain samples and RNAscope in situ hybridization. OP and JCT provided the postmortem AD and control brain samples with Braak staining stages and gave invaluable advice for the manuscript. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar3">
<title>Ethics approval and consent to participate</title>
<p>The experiments on the postmortem brain tissues ware approved by John Hopkins Medicine Institutional Review Board (<ext-link ext-link-type="uri" xlink:href="https://www.hopkinsmedicine.org/institutional_review_board/index.html">https://www.hopkinsmedicine.org/institutional_review_board/index.html</ext-link>).</p>
</sec>
<sec id="FPar4">
<title>Consent for publication</title>
<p>Publication clearance by NIA/NIH.</p>
</sec>
<sec id="FPar5">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar6">
<title>Publisher’s Note</title>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>YP</given-names>
</name>
<name>
<surname>Sisodia</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Abeta star: a light onto synaptic dysfunction?</article-title>
<source/>Nat Med
          <year>2006</year>
<volume>12</volume>
<issue>7</issue>
<fpage>760</fpage>
<lpage>761</lpage>
<pub-id pub-id-type="pmid">16829934</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Malenka</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Tabuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Presynaptic neurexin-3 alternative splicing trans-synaptically controls postsynaptic AMPA receptor trafficking</article-title>
<source/>Cell
          <year>2013</year>
<volume>154</volume>
<issue>1</issue>
<fpage>75</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="pmid">23827676</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coon</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Lince</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Zismann</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Beach</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bryden</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease</article-title>
<source/>J Clin Psychiatry
          <year>2007</year>
<volume>68</volume>
<issue>4</issue>
<fpage>613</fpage>
<lpage>618</lpage>
<pub-id pub-id-type="pmid">17474819</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Madison</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Crowley</surname>
<given-names>S</given-names>
</name>
<name>
<surname>O'Neil</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Jagust</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Neural compensation in older people with brain amyloid-beta deposition</article-title>
<source/>Nat Neurosci
          <year>2014</year>
<volume>17</volume>
<issue>10</issue>
<fpage>1316</fpage>
<lpage>1318</lpage>
<pub-id pub-id-type="pmid">25217827</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pletnikova</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rudow</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Hyde</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Kleinman</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>SZ</given-names>
</name>
<name>
<surname>Bharadwaj</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gangadeen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Crain</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Rubio</surname>
<given-names>AI</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alzheimer lesions in the autopsied brains of people 30 to 50 years of age</article-title>
<source/>Cogn Behav Neurol
          <year>2015</year>
<volume>28</volume>
<issue>3</issue>
<fpage>144</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="pmid">26413742</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iacono</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Resnick</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>O'Brien</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zonderman</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>An</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pletnikova</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Rudow</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Crain</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Troncoso</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent beta-amyloid and tau loads with divergent cognitive outcomes</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2014</year>
<volume>73</volume>
<issue>4</issue>
<fpage>295</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="pmid">24607960</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Priller</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mitteregger</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Krebs</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kretzschmar</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Herms</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Synapse formation and function is modulated by the amyloid precursor protein</article-title>
<source/>J Neurosci
          <year>2006</year>
<volume>26</volume>
<issue>27</issue>
<fpage>7212</fpage>
<lpage>7221</lpage>
<pub-id pub-id-type="pmid">16822978</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viola</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Velasco</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>WL</given-names>
</name>
</person-group>
<article-title>Why Alzheimer’s is a disease of memory: the attack on synapses by a beta oligomers (ADDLs)</article-title>
<source/>J Nutr Health Aging
          <year>2008</year>
<volume>12</volume>
<issue>1</issue>
<fpage>51S</fpage>
<lpage>57S</lpage>
<pub-id pub-id-type="pmid">18165846</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ushkaryov</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Petrenko</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Geppert</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Neurexins: synaptic cell surface proteins related to the alpha-latrotoxin receptor and laminin</article-title>
<source/>Science
          <year>1992</year>
<volume>257</volume>
<issue>5066</issue>
<fpage>50</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">1621094</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>QR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>OKCAM: an ontology-based, human-centered knowledgebase for cell adhesion molecules</article-title>
<source/>Nucleic Acids Res
          <year>2009</year>
<volume>37</volume>
<issue>Database issue</issue>
<fpage>D251</fpage>
<lpage>D260</lpage>
<pub-id pub-id-type="pmid">18790807</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Missler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Neurexins: three genes and 1001 products</article-title>
<source/>Trends Genet
          <year>1998</year>
<volume>14</volume>
<issue>1</issue>
<fpage>20</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="pmid">9448462</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Neuroligins and neurexins link synaptic function to cognitive disease</article-title>
<source/>Nature
          <year>2008</year>
<volume>455</volume>
<issue>7215</issue>
<fpage>903</fpage>
<lpage>911</lpage>
<pub-id pub-id-type="pmid">18923512</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Missler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rohlmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kattenstroth</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hammer</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Gottmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis</article-title>
<source/>Nature
          <year>2003</year>
<volume>423</volume>
<issue>6943</issue>
<fpage>939</fpage>
<lpage>948</lpage>
<pub-id pub-id-type="pmid">12827191</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rudenko</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Dynamic control of synaptic adhesion and organizing molecules in synaptic plasticity</article-title>
<source/>Neural Plast
          <year>2017</year>
<volume>2017</volume>
<fpage>6526151</fpage>
<pub-id pub-id-type="pmid">28255461</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Synaptic neurexin complexes: a molecular code for the logic of neural circuits</article-title>
<source/>Cell
          <year>2017</year>
<volume>171</volume>
<issue>4</issue>
<fpage>745</fpage>
<lpage>769</lpage>
<pub-id pub-id-type="pmid">29100073</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biederer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Mints as adaptors. Direct binding to neurexins and recruitment of munc18</article-title>
<source/>J Biol Chem
          <year>2000</year>
<volume>275</volume>
<issue>51</issue>
<fpage>39803</fpage>
<lpage>39806</lpage>
<pub-id pub-id-type="pmid">11036064</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hata</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Butz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>CASK: a novel dlg/PSD95 homolog with an N-terminal calmodulin-dependent protein kinase domain identified by interaction with neurexins</article-title>
<source/>J Neurosci
          <year>1996</year>
<volume>16</volume>
<issue>8</issue>
<fpage>2488</fpage>
<lpage>2494</lpage>
<pub-id pub-id-type="pmid">8786425</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Hamel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Amyloid-beta oligomers interact with neurexin and diminish neurexin-mediated excitatory presynaptic organization</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<fpage>42548</fpage>
<pub-id pub-id-type="pmid">28211900</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>McLoughlin</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Tennant</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Rogelj</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The X11 proteins, Abeta production and Alzheimer’s disease</article-title>
<source/>Trends Neurosci
          <year>2006</year>
<volume>29</volume>
<issue>5</issue>
<fpage>280</fpage>
<lpage>285</lpage>
<pub-id pub-id-type="pmid">16545469</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hishimoto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>QR</given-names>
</name>
<name>
<surname>Drgon</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pletnikova</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>XG</given-names>
</name>
<name>
<surname>Troncoso</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms</article-title>
<source/>Hum Mol Genet
          <year>2007</year>
<volume>16</volume>
<issue>23</issue>
<fpage>2880</fpage>
<lpage>2891</lpage>
<pub-id pub-id-type="pmid">17804423</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ushkaryov</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Neurexin III alpha: extensive alternative splicing generates membrane-bound and soluble forms</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1993</year>
<volume>90</volume>
<issue>14</issue>
<fpage>6410</fpage>
<lpage>6414</lpage>
<pub-id pub-id-type="pmid">8341647</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Aoto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tabuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Foldy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Covy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yee</surname>
<given-names>AX</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Malenka</surname>
<given-names>RC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>beta-Neurexins control neural circuits by regulating synaptic endocannabinoid signaling</article-title>
<source/>Cell
          <year>2015</year>
<volume>162</volume>
<issue>3</issue>
<fpage>593</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="pmid">26213384</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bot</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schweizer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ben Halima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fraering</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>Processing of the synaptic cell adhesion molecule neurexin-3beta by Alzheimer disease alpha- and gamma-secretases</article-title>
<source/>J Biol Chem
          <year>2011</year>
<volume>286</volume>
<issue>4</issue>
<fpage>2762</fpage>
<lpage>2773</lpage>
<pub-id pub-id-type="pmid">21084300</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alarcon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abrahams</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Duvall</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Perederiy</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Bomar</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sebat</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wigler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Ledbetter</surname>
<given-names>DH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene</article-title>
<source/>Am J Hum Genet
          <year>2008</year>
<volume>82</volume>
<issue>1</issue>
<fpage>150</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="pmid">18179893</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arking</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Brune</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Teslovich</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>West</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rea</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>EH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism</article-title>
<source/>Am J Hum Genet
          <year>2008</year>
<volume>82</volume>
<issue>1</issue>
<fpage>160</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="pmid">18179894</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Kishikawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Seong</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Donovan</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lally</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Najm</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kutsche</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disruption of neurexin 1 associated with autism spectrum disorder</article-title>
<source/>Am J Hum Genet
          <year>2008</year>
<volume>82</volume>
<issue>1</issue>
<fpage>199</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="pmid">18179900</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bierut</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Madden</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Breslau</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>EO</given-names>
</name>
<name>
<surname>Hatsukami</surname>
<given-names>D</given-names>
</name>
<collab>Pomerleau OF</collab>
<name>
<surname>Swan</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bertelsen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel genes identified in a high-density genome wide association study for nicotine dependence</article-title>
<source/>Hum Mol Genet
          <year>2007</year>
<volume>16</volume>
<issue>1</issue>
<fpage>24</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">17158188</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lachman</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Fann</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Bartzis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Evgrafov</surname>
<given-names>OV</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Nunes</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Miner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Santana</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gaffney</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Riddick</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genomewide suggestive linkage of opioid dependence to chromosome 14q</article-title>
<source/>Hum Mol Genet
          <year>2007</year>
<volume>16</volume>
<issue>11</issue>
<fpage>1327</fpage>
<lpage>1334</lpage>
<pub-id pub-id-type="pmid">17409192</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirov</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gumus</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Norton</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Georgieva</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>O'Donovan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Erdogan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Ropers</surname>
<given-names>HH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia</article-title>
<source/>Hum Mol Genet
          <year>2008</year>
<volume>17</volume>
<issue>3</issue>
<fpage>458</fpage>
<lpage>465</lpage>
<pub-id pub-id-type="pmid">17989066</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rujescu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ingason</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cichon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pietilainen</surname>
<given-names>OP</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Toulopoulou</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Picchioni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vassos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ettinger</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Bramon</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disruption of the neurexin 1 gene is associated with schizophrenia</article-title>
<source/>Hum Mol Genet
          <year>2009</year>
<volume>18</volume>
<issue>5</issue>
<fpage>988</fpage>
<lpage>996</lpage>
<pub-id pub-id-type="pmid">18945720</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoto</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Foldy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ilcus</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Tabuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Distinct circuit-dependent functions of presynaptic neurexin-3 at GABAergic and glutamatergic synapses</article-title>
<source/>Nat Neurosci
          <year>2015</year>
<volume>18</volume>
<issue>7</issue>
<fpage>997</fpage>
<lpage>1007</lpage>
<pub-id pub-id-type="pmid">26030848</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>WX</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>JQ</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>SX</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Low expression of aging-related NRXN3 is associated with Alzheimer disease: a systematic review and meta-analysis</article-title>
<source/>Medicine (Baltimore)
          <year>2018</year>
<volume>97</volume>
<issue>28</issue>
<fpage>e11343</fpage>
<pub-id pub-id-type="pmid">29995770</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Braak</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Neuropathological staging of Alzheimer-related changes</article-title>
<source/>Acta Neuropathol
          <year>1991</year>
<volume>82</volume>
<issue>4</issue>
<fpage>239</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="pmid">1759558</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bobinski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Leon</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Wegiel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Desanti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Convit</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Saint Louis</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Rusinek</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>HM</given-names>
</name>
</person-group>
<article-title>The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease</article-title>
<source/>Neuroscience
          <year>2000</year>
<volume>95</volume>
<issue>3</issue>
<fpage>721</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="pmid">10670438</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Troncoso</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Cataldo</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Nixon</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Barnett</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Checler</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Smialek</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Crain</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>LJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropathology of preclinical and clinical late-onset Alzheimer’s disease</article-title>
<source/>Ann Neurol
          <year>1998</year>
<volume>43</volume>
<issue>5</issue>
<fpage>673</fpage>
<lpage>676</lpage>
<pub-id pub-id-type="pmid">9585365</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edenberg</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Bierut</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Boyce</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cawley</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chiles</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Doheny</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hinrichs</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Description of the data from the Collaborative Study on the Genetics of Alcoholism (COGA) and single-nucleotide polymorphism genotyping for Genetic Analysis Workshop 14</article-title>
<source/>BMC Genet
          <year>2005</year>
<volume>6</volume>
<issue>Suppl 1</issue>
<fpage>S2</fpage>
<pub-id pub-id-type="pmid">16451628</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>QR</given-names>
</name>
<name>
<surname>Drgon</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Addiction molecular genetics: 639,401 SNP whole genome association identifies many “cell adhesion” genes</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2006</year>
<volume>141B</volume>
<issue>8</issue>
<fpage>918</fpage>
<lpage>925</lpage>
<pub-id pub-id-type="pmid">17099884</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wenham</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Blandell</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Apolipoprotein E genotyping by one-stage PCR</article-title>
<source/>Lancet
          <year>1991</year>
<volume>337</volume>
<issue>8750</issue>
<fpage>1158</fpage>
<lpage>1159</lpage>
<pub-id pub-id-type="pmid">1674030</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doyle</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Fiori</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Gonzalez Mariscal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>QR</given-names>
</name>
<name>
<surname>Goodstein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Santa-Cruz Calvo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Indig</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Insulin is transcribed and translated in mammalian taste bud cells</article-title>
<source/>Endocrinology
          <year>2018</year>
<volume>159</volume>
<issue>9</issue>
<fpage>3331</fpage>
<lpage>3339</lpage>
<pub-id pub-id-type="pmid">30060183</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dupont</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Plummer</surname>
<given-names>WD</given-names>
<suffix>Jr</suffix>
</name>
</person-group>
<article-title>Power and sample size calculations for studies involving linear regression</article-title>
<source/>Control Clin Trials
          <year>1998</year>
<volume>19</volume>
<issue>6</issue>
<fpage>589</fpage>
<lpage>601</lpage>
<pub-id pub-id-type="pmid">9875838</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heneka</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Kummer</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Stutz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Delekate</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vieira-Saecker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Griep</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Axt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Remus</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tzeng</surname>
<given-names>TC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice</article-title>
<source/>Nature
          <year>2013</year>
<volume>493</volume>
<issue>7434</issue>
<fpage>674</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="pmid">23254930</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Rourke</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Weiler</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Micheva</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Deep molecular diversity of mammalian synapses: why it matters and how to measure it</article-title>
<source/>Nat Rev Neurosci
          <year>2012</year>
<volume>13</volume>
<issue>6</issue>
<fpage>365</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="pmid">22573027</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spires-Jones</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>BT</given-names>
</name>
</person-group>
<article-title>The intersection of amyloid beta and tau at synapses in Alzheimer’s disease</article-title>
<source/>Neuron
          <year>2014</year>
<volume>82</volume>
<issue>4</issue>
<fpage>756</fpage>
<lpage>771</lpage>
<pub-id pub-id-type="pmid">24853936</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kay</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Serrano-Pozo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pooler</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Koffie</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bastin</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Bak</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Abrahams</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kopeikina</surname>
<given-names>KJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Studying synapses in human brain with array tomography and electron microscopy</article-title>
<source/>Nat Protoc
          <year>2013</year>
<volume>8</volume>
<issue>7</issue>
<fpage>1366</fpage>
<lpage>1380</lpage>
<pub-id pub-id-type="pmid">23787894</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<mixed-citation publication-type="other">Richter MC, Ludewig S, Winschel A, Abel T, Bold C, Salzburger LR, Klein S, Han K, Weyer SW, Fritz AK, et al. Distinct in vivo roles of secreted APP ectodomain variants APPsalpha and APPsbeta in regulation of spine density, synaptic plasticity, and cognition. EMBO J. 2018;37(11). 10.15252/embj.201798335.</mixed-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lane-Donovan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Herz</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>ApoE, ApoE receptors, and the synapse in Alzheimer’s disease</article-title>
<source/>Trends Endocrinol Metab
          <year>2017</year>
<volume>28</volume>
<issue>4</issue>
<fpage>273</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="pmid">28057414</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salazar</surname>
<given-names>SV</given-names>
</name>
<collab>Cox TO</collab>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brody</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Chyung</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Strittmatter</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease risk factor Pyk2 mediates amyloid-beta-induced synaptic dysfunction and loss</article-title>
<source/>J Neurosci
          <year>2019</year>
<volume>39</volume>
<issue>4</issue>
<fpage>758</fpage>
<lpage>772</lpage>
<pub-id pub-id-type="pmid">30518596</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiocco</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pletnikova</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Troncoso</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>QR</given-names>
</name>
</person-group>
<article-title>Fine mapping of calcineurin (PPP3CA) gene reveals novel alternative splicing patterns, association of 5′UTR trinucleotide repeat with addiction vulnerability, and differential isoform expression in Alzheimer’s disease</article-title>
<source/>Subst Use Misuse
          <year>2010</year>
<volume>45</volume>
<issue>11</issue>
<fpage>1809</fpage>
<lpage>1826</lpage>
<pub-id pub-id-type="pmid">20590401</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cruchaga</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kauwe</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Mayo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bertelsen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nowotny</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hollingworth</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Harold</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer’s disease</article-title>
<source/>PLoS Genet
          <year>2010</year>
<volume>6</volume>
<issue>9</issue>
<fpage>e1001101</fpage>
<pub-id pub-id-type="pmid">20862329</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<mixed-citation publication-type="other">Stallings NR, O'Neal MA, Hu J, Kavalali ET, Bezprozvanny I, Malter JS. Pin1 mediates Abeta42-induced dendritic spine loss. Sci Signal. 2018;11(522). 10.1126/scisignal.aap8734.</mixed-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thaiss</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Elinav</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Taming the inflammasome</article-title>
<source/>Nat Med
          <year>2015</year>
<volume>21</volume>
<issue>3</issue>
<fpage>213</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="pmid">25742454</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Supnet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bezprozvanny</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer’s disease</article-title>
<source/>J Alzheimers Dis
          <year>2010</year>
<volume>20</volume>
<issue>Suppl 2</issue>
<fpage>S487</fpage>
<lpage>S498</lpage>
<pub-id pub-id-type="pmid">20413848</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Hudry</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kuchibhotla</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rozkalne</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Spires-Jones</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Arbel-Ornath</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grosskreutz</surname>
<given-names>CL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation</article-title>
<source/>J Neurosci
          <year>2010</year>
<volume>30</volume>
<issue>7</issue>
<fpage>2636</fpage>
<lpage>2649</lpage>
<pub-id pub-id-type="pmid">20164348</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holtzman</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Goate</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease: the challenge of the second century</article-title>
<source/>Sci Transl Med
          <year>2011</year>
<volume>3</volume>
<issue>77</issue>
<fpage>77sr71</fpage>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wetten</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>St Jean</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Upmanyu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Surh</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hosford</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Briley</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Borrie</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease</article-title>
<source/>Arch Neurol
          <year>2008</year>
<volume>65</volume>
<issue>1</issue>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">17998437</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reiman</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dunckley</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zismann</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Joshipura</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Hu-Lince</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Huentelman</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GAB2 alleles modify Alzheimer’s risk in APOE epsilon4 carriers</article-title>
<source/>Neuron
          <year>2007</year>
<volume>54</volume>
<issue>5</issue>
<fpage>713</fpage>
<lpage>720</lpage>
<pub-id pub-id-type="pmid">17553421</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertram</surname>
<given-names>L</given-names>
</name>
<name>
<surname>McQueen</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Mullin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Blacker</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tanzi</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database</article-title>
<source/>Nat Genet
          <year>2007</year>
<volume>39</volume>
<issue>1</issue>
<fpage>17</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">17192785</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Verghese</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Joung</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Ulrich</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Holtzman</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Barres</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2016</year>
<volume>113</volume>
<issue>36</issue>
<fpage>10186</fpage>
<lpage>10191</lpage>
<pub-id pub-id-type="pmid">27559087</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Octave</surname>
<given-names>JN</given-names>
</name>
</person-group>
<article-title>The amyloid peptide precursor in Alzheimer’s disease</article-title>
<source/>Acta Neurol Belg
          <year>1995</year>
<volume>95</volume>
<issue>4</issue>
<fpage>197</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="pmid">8553793</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kero</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Paetau</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Polvikoski</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tanskanen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sulkava</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jansson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Myllykangas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tienari</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population</article-title>
<source/>Neurobiol Aging
          <year>2013</year>
<volume>34</volume>
<issue>5</issue>
<fpage>1518</fpage>
<pub-id pub-id-type="pmid">23102935</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terry</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Cell death or synaptic loss in Alzheimer disease</article-title>
<source/>J Neuropathol Exp Neurol
          <year>2000</year>
<volume>59</volume>
<issue>12</issue>
<fpage>1118</fpage>
<lpage>1119</lpage>
<pub-id pub-id-type="pmid">11138931</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azevedo</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Grinberg</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Farfel</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ferretti</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Leite</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Jacob Filho</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lent</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Herculano-Houzel</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain</article-title>
<source/>J Comp Neurol
          <year>2009</year>
<volume>513</volume>
<issue>5</issue>
<fpage>532</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="pmid">19226510</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brito-Moreira</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lourenco</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Ledo</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Diniz</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Vital</surname>
<given-names>JFS</given-names>
</name>
<name>
<surname>Magdesian</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Melo</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Barros-Aragao</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interaction of amyloid-beta (Abeta) oligomers with neurexin 2alpha and neuroligin 1 mediates synapse damage and memory loss in mice</article-title>
<source/>J Biol Chem
          <year>2017</year>
<volume>292</volume>
<issue>18</issue>
<fpage>7327</fpage>
<lpage>7337</lpage>
<pub-id pub-id-type="pmid">28283575</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quinn</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Kolar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wigerius</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gomm-Kolisko</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Atwi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fawcett</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>SR</given-names>
</name>
</person-group>
<article-title>Pan-neurexin perturbation results in compromised synapse stability and a reduction in readily releasable synaptic vesicle pool size</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<fpage>42920</fpage>
<pub-id pub-id-type="pmid">28220838</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Endocannabinoid mediates excitatory synaptic function of beta-neurexins. Commentary: beta-neurexins control neural circuits by regulating synaptic endocannabinoid signaling</article-title>
<source/>Front Neurosci
          <year>2016</year>
<volume>10</volume>
<fpage>203</fpage>
<pub-id pub-id-type="pmid">27242408</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schenk</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Verderio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Benfenati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Matteoli</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Regulated delivery of AMPA receptor subunits to the presynaptic membrane</article-title>
<source/>EMBO J
          <year>2003</year>
<volume>22</volume>
<issue>3</issue>
<fpage>558</fpage>
<lpage>568</lpage>
<pub-id pub-id-type="pmid">12554656</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>X</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>QR</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>ZX</given-names>
</name>
</person-group>
<article-title>CB1 receptor activation on VgluT2-expressing glutamatergic neurons underlies delta(9)-tetrahydrocannabinol (delta(9)-THC)-induced aversive effects in mice</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>12315</fpage>
<pub-id pub-id-type="pmid">28951549</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>QR</given-names>
</name>
<name>
<surname>Canseco-Alba</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Tagliaferro</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sanabria</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schanz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Escosteguy-Neto</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Ishiguro</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>17410</fpage>
<pub-id pub-id-type="pmid">29234141</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brusco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tagliaferro</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Saez</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Onaivi</surname>
<given-names>ES</given-names>
</name>
</person-group>
<article-title>Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus</article-title>
<source/>Synapse
          <year>2008</year>
<volume>62</volume>
<issue>12</issue>
<fpage>944</fpage>
<lpage>949</lpage>
<pub-id pub-id-type="pmid">18798269</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bilkei-Gorzo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Albayram</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Draffehn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Piyanova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oppenheimer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dvir-Ginzberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Racz</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ulas</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Imbeault</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A chronic low dose of delta(9)-tetrahydrocannabinol (THC) restores cognitive function in old mice</article-title>
<source/>Nat Med
          <year>2017</year>
<volume>23</volume>
<issue>6</issue>
<fpage>782</fpage>
<lpage>787</lpage>
<pub-id pub-id-type="pmid">28481360</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarne</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Toledano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rachmany</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sasson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Doron</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Reversal of age-related cognitive impairments in mice by an extremely low dose of tetrahydrocannabinol</article-title>
<source/>Neurobiol Aging
          <year>2018</year>
<volume>61</volume>
<fpage>177</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="pmid">29107185</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<mixed-citation publication-type="other">Brinkmalm G, Sjodin S, Simonsen AH, Hasselbalch SG, Zetterberg H, Brinkmalm A, Blennow K. A parallel reaction monitoring mass spectrometric method for analysis of potential CSF biomarkers for Alzheimer’s disease. Proteomics Clin Appl. 2018;12(1). 10.1002/prca.201700131.</mixed-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duits</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Brinkmalm</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Teunissen</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Brinkmalm</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scheltens</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Van der Flier</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Zetterberg</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Blennow</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease</article-title>
<source/>Alzheimers Res Ther
          <year>2018</year>
<volume>10</volume>
<issue>1</issue>
<fpage>5</fpage>
<pub-id pub-id-type="pmid">29370833</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sterky</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Trotter</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Recktenwald</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schwenk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fakler</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sudhof</surname>
<given-names>TC</given-names>
</name>
</person-group>
<article-title>Carbonic anhydrase-related protein CA10 is an evolutionarily conserved pan-neurexin ligand</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2017</year>
<volume>114</volume>
<issue>7</issue>
<fpage>E1253</fpage>
<lpage>E1262</lpage>
<pub-id pub-id-type="pmid">28154140</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khalsa</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>Stress, meditation, and Alzheimer’s disease prevention: where the evidence stands</article-title>
<source/>J Alzheimers Dis
          <year>2015</year>
<volume>48</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">26445019</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>